How Nanobody Drugs Are Opening a New Path for Aggressive Cancers Like Triple-Negative Breast Cancer
Nanobody drugs are smaller than full antibodies and may reach intracellular targets like mutant p53. A 2026 look at early TNBC research in model systems.




